top of page
  • LKY

Why Are Eggs so Expensive??

Where’d the Eggs Go? Multiple Studies Show Egg Yolk Antibodies Block the Binding of Multiple SARS-CoV-2 (Covid-19) Spike Protein Variants in BOMBSHELL REPORT

LKY: We in Montezuma county are so blessed to have so many home egg growers here that we don't always have to rely on the grocery store for our eggs. I thought this article was amazing that it might explain why we have this "egg" problem. I know that this article is rather involved. It is difficult to follow all the scientific stuff. But I copied it all because they are showing the PROOF that there ARE THESE STUDIES. If you google "egg antibodies to COVID" you get line after line of "misinformation, disinformation, false information". so who do you want to believe?

Feb. 1, 2023 by Howard Roark NEWS from The DC Patriot You know how there’s a massive egg shortage and egg farms keep burning down all over America? Eggs are now over $10 per dozen in many places. Meanwhile you keep asking yourself “Why is this happening, sure seems odd?” Well, we might have the answer to that, and conspiracy theorists be damned. Chicken Egg Yolk Antibodies block the binding of multiple SARS-CoV-2 Spike Protein Variants to human ACE2. We’re serious, and we’ve got the studies, links, and it’s all from our own National Institute of Health right here in America. Is that why eggs are disappearing at an alarming rate? Is that why chicken farms are being destroyed? We don’t know, but it sure is a “what the hell is happening here” moment, isn’t it? This is absolutely astonishing, as we were just pointed to this late Wednesday afternoon. The National Institute of Health’s own studies shows that Chicken Egg Yolk antibodies actually block the binding of multiple SARS-COV-2 Spike protein variants to human ACE2. The following is literally and directly from the National Institute of Health’s website. Click here for the link, but we’ve added the information below as well.

The SARS-CoV-2 virus is still spreading worldwide, and there is an urgent need to effectively prevent and control this pandemic. This study evaluated the potential efficacy of Egg Yolk Antibodies (IgY) as a neutralizing agent against the SARS-CoV-2. We investigated the neutralizing effect of anti-spike-S1 IgYs on the SARS-CoV-2 pseudovirus, as well as its inhibitory effect on the binding of the coronavirus spike protein mutants to human ACE2. Our results show that the anti-Spike-S1 IgYs showed significant neutralizing potency against SARS-CoV-2 pseudovirus, various spike protein mutants, and even SARS-CoV in vitro. It might be a feasible tool for the prevention and control of ongoing COVID-19. It might be a feasible took for the prevention and control of ongoing Covid-19????? Y’all don’t think this was some good information to have 3 years ago? Really? Unbelievable isn’t it! . Here’s other articles on it as well folks, even in November of 2022. We’ve added two other studies below from the NIH website, it’s literally there, no one looked for it. Is this why there is a massive egg shortage in America?

Immunoglobulin yolk targeting spike 1, receptor binding domain of spike glycoprotein and nucleocapsid of SARS-CoV-2 blocking RBD-ACE2 binding interaction Click here to read the study from Elsevier B.V Meliana Eka Saputri 1, Siti Aisyah Rahmalia Effendi 2, Rifa Nadila 2, Syauqi Azzam Fajar 2, Retno Damajanti Soejoedono 3, Ekowati Handharyani 4, Okti Nadia Poetri 5 PMID: 36183680

  • PMCID: PMC9515349

  • DOI: 10.1016/j.intimp.2022.109280

Free PMC article Abstract Coronavirus disease (COVID)-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has become a global pandemic disease that has social and economic chaos. An alternative mitigation strategy may involve the use of specific immunoglobulin (Ig)-Y derived from chicken eggs. Our study aimed to evaluate the neutralizing potential of specific IgY targeting S1, receptor-binding-domain (RBD) of spike glycoprotein and nucleocapsid (N) of SARS-CoV-2 to inhibit RBD and angiotensin-converting-enzyme-2 (ACE2) binding interaction. Hy-Line Brown laying hens were immunized with recombinant S1, RBD spike glycoprotein, and nucleocapsid (N) of SARS-CoV-2. The presence of specific S1,RBD,N-IgY in serum and egg yolk was verified by indirect enzyme-linked immunosorbent assay (ELISA). Specific S1,RBD,N-IgY was purified and characterized from egg yolk using sodium-dodecyl-sulfate-polyacrylamide-gel-electrophoresis (SDS-PAGE), and was subsequently evaluated for inhibition of the RBD-ACE2 binding interaction in vitro. Specific IgY was present in serum at 1 week post-initial immunization (p.i.i), whereas its present in egg yolk was confirmed at 4 weeks p.i.i. Specific S1,RBD,N-IgY in serum was able to inhibit RBD-ACE2 binding interaction between 4 and 15 weeks p.i.i. The results of the SDS-PAGE revealed the presence of bands with molecular weights of 180 kDa, indicating the presence of whole IgY. Our results demonstrated that S1,RBD,N-IgY was able to inhibit RBD-ACE2 binding interaction in vitro, suggesting its potential use in blocking virus entry. Our study also demonstrated proof-of-concept that laying hens were able to produce this specific IgY, which could block the viral binding and large production of this specific IgY is feasible. Keywords: Angiotensin-converting-enzyme-2; Binding interaction; Immunoglobulin Y; Laying hens; Receptor-binding-domain; SARS-CoV-2. Copyright © 2022 Elsevier B.V. All rights reserved. Conflict of interest statement Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Egg yolk immunoglobulin (IgY) targeting SARS-CoV-2 S1 as potential virus entry blocker Click here to read the study from The Society of Applied Microbiology Lirong Bao 1, Cheng Zhang 1, Jinglu Lyu 1, Ping Yi 1 2, Xin Shen 1, Boyu Tang 1, Hang Zhao 1, Biao Ren 1, Yu Kuang 3, Linlin Zhou 3, Yan Li 1

  • PMID: 34706134

  • PMCID: PMC8657347

  • DOI: 10.1111/jam.15340

Free PMC article Abstract Aims: COVID-19 pandemic caused by SARS-CoV-2 has become a public health crisis worldwide. In this study, we aimed at demonstrating the neutralizing potential of the IgY produced after immunizing chicken with a recombinant SARS-CoV-2 spike protein S1 subunit. Methods and results: E. coli BL21 carrying plasmid pET28a-S1 was induced with IPTG for the expression of SARS-CoV-2 S1 protein. The recombinant His-tagged S1 was purified and verified by SDS-PAGE, Western blot and biolayer interferometry (BLI) assay. Then S1 protein emulsified with Freund’s adjuvant was used to immunize layer chickens. Specific IgY against S1 (S1-IgY) produced from egg yolks of these chickens exhibited a high titer (1:25,600) and a strong binding affinity to S1 (KD = 318 nmol L-1 ). The neutralizing ability of S1-IgY was quantified by a SARS-CoV-2 pseudotyped virus-based neutralization assay with an IC50 value of 0.99 mg ml-1 . In addition, S1-IgY exhibited a strong ability in blocking the binding of SARS-CoV-2 S1 to hACE2, and it could partially compete with hACE2 for the binding sites on S1 by BLI assays. Conclusions: We demonstrated here that after immunization of chickens with our recombinant S1 protein, IgY neutralizing antibodies were generated against the SARS-CoV-2 spike protein S1 subunit; therefore, showing the potential use of IgY to block the entry of this virus. Significance and impact of the study: IgY targeting S1 subunit of SARS-CoV-2 could be a promising candidate for pre- and post-exposure prophylaxis or treatment of COVID-19. Administration of IgY-based oral preparation, oral or nasal spray may have profound implications for blocking SARS-CoV-2. © 2021 The Society for Applied Microbiology.

But wait, there’s more! Here’s another study showing the exact same thing, all of these are documented, no one just did the work to look into this, and now we have a massive egg shortage? How much coincidence do you believe in anymore?

Generation of Chicken IgY against SARS-COV-2 Spike Protein and Epitope Mapping Yan Lu 1, Yajun Wang 2, Zhen Zhang 3, Jingliang Huang 4, Meicun Yao 5, Guobin Huang 6, Yuanyuan Ge 6, Peichun Zhang 1, Huaxin Huang 1, Yong Wang 7, Huiliang Li 2, Wen Wang 1 Click here to read the study from Yan Lu et al.

  • PMID: 33134398

  • PMCID: PMC7568776

  • DOI: 10.1155/2020/9465398

Free PMC article Abstract This new decade has started with a global pandemic of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), precipitating a worldwide health crisis and economic downturn. Scientists and clinicians have been racing against time to find therapies for COVID-19. Repurposing approved drugs, developing vaccines and employing passive immunization are three major therapeutic approaches to fighting COVID-19. Chicken immunoglobulin Y (IgY) has the potential to be used as neutralizing antibody against respiratory infections, and its advantages include high avidity, low risk of adverse immune responses, and easy local delivery by intranasal administration. In this study, we raised antibody against the spike (S) protein of SARS-CoV-2 in chickens and extracted IgY (called IgY-S) from egg yolk. IgY-S exhibited high immunoreactivity against SARS-CoV-2 S, and by epitope mapping, we found five linear epitopes of IgY-S in SARS-CoV-2 S, two of which are cross-reactive with SARS-CoV S. Notably, epitope SIIAYTMSL, one of the identified epitopes, partially overlaps the S1/S2 cleavage region in SARS-CoV-2 S and is located on the surface of S trimer in 3D structure, close to the S1/S2 cleavage site. Thus, antibody binding at this location could physically block the access of proteolytic enzymes to S1/S2 cleavage site and thereby impede S1/S2 proteolytic cleavage, which is crucial to subsequent virus-cell membrane fusion and viral cell entry. Therefore, the feasibility of using IgY-S or epitope SIIAYTMS-specific IgY as neutralizing antibody for preventing or treating SARS-CoV-2 infection is worth exploring. Copyright © 2020 Yan Lu et al. Conflict of interest statement All authors declare no conflict of interest.

Even the folks over at UC Davis found this study back in the summer of 2022 and no one listened. Check it out here.

The following is from Andy Fell at UC Davis: What do you think folks, is this just some big coincidence, or are we onto something? Comment below, we’d love to hear from you!

Researchers at the University of California, Davis, have been able to produce antibodies to the SARS-CoV-2 spike protein in hen eggs. Antibodies harvested from eggs might be used to treat COVID-19 or as a preventative measure for people exposed to the disease. The work was published July 9 in the journal Viruses. “The beauty of the system is that you can produce a lot of antibodies in birds,” said Rodrigo Gallardo, professor in poultry medicine, Department of Population Health and Reproduction at the UC Davis School of Veterinary Medicine. “In addition to a low cost to produce these antibodies in hens, they can be updated very fast by using updated antigens to hyperimmunize hens, allowing protection against current variant strains.” Birds produce a type of antibody called IgY, comparable to IgG in humans and other mammals. IgY does not cause allergy or set off immune reactions when injected into humans. IgY appears both in birds’ serum and in their eggs. As a hen lays about 300 eggs a year, you can get a lot of IgY, Gallardo said. Gallardo and colleagues immunized hens with two doses of three different vaccines based on the SARS-CoV-2 spike protein or receptor binding domain. They measured antibodies in blood samples from the hens and in egg yolks three and six weeks after the last immunization. Purified antibodies were tested for their ability to block coronavirus from infecting human cells at the National Center for Biodefense and Infectious Diseases at George Mason University in Virginia. Both eggs and sera from immunized hens contained antibodies that recognized SARS-CoV-2. Antibodies from serum were more effective in neutralizing the virus, probably because there is more antibody in blood overall, Gallardo said. Gallardo is working with colleagues Daria Mochly-Rosen at Stanford University and Michael Wallach, University of Technology, Sydney, to develop the egg-based antibody technology. The team hopes to deploy these antibodies in a preventative treatment such as a spray, that could be used by people at high risk of exposure to coronavirus. Additional authors on the paper are Emily Aston, UC Davis Department of Animal Science; Aarthi Narayanan, National Center for Biodefense and Infectious Diseases; and Sofia Egaña-Labrin, UC Davis School of Veterinary Medicine. The work was supported by the School of Veterinary Medicine at UC Davis, Stanford University and poultry producers in the state of California.

32 views0 comments
bottom of page